FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891131325> ?p ?o ?g. }

• W2891131325 endingPage "1155" @default.
• W2891131325 startingPage "1146" @default.
• W2891131325 abstract "Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response.The purpose of this study was to analyze disease-free and overall survival.This was a nonrandomized phase II trial.The study was conducted at multiple institutions.Four sequential study groups with stage II or III rectal cancer were included.All of the patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of modified FOLFOX6 after chemoradiation and before total mesorectal excision. Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of modified FOLFOX6.The trial was powered to detect differences in pathological complete response, which was reported previously. Disease-free and overall survival are the main outcomes for the current study.Of 259 patients, 211 had a complete follow-up. Median follow-up was 59 months (range, 9-125 mo). The mean number of total chemotherapy cycles differed among the 4 groups (p = 0.002), because one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. Disease-free survival was significantly associated with study group, ypTNM stage, and pathological complete response (p = 0.004, <0.001, and 0.001). A secondary analysis including only patients who received ≥1 cycle of FOLFOX still showed differences in survival between study groups (p = 0.03).The trial was not randomized and was not powered to show differences in survival. Survival data were not available for 19% of the patients.Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. See Video Abstract at http://links.lww.com/DCR/A739." @default.
• W2891131325 created "2018-09-27" @default.
• W2891131325 creator A5004074211 @default.
• W2891131325 creator A5010136395 @default.
• W2891131325 creator A5015050276 @default.
• W2891131325 creator A5016541773 @default.
• W2891131325 creator A5026922437 @default.
• W2891131325 creator A5027858056 @default.
• W2891131325 creator A5029701783 @default.
• W2891131325 creator A5044015707 @default.
• W2891131325 creator A5047787817 @default.
• W2891131325 creator A5060087499 @default.
• W2891131325 creator A5060248836 @default.
• W2891131325 creator A5063518326 @default.
• W2891131325 creator A5064525249 @default.
• W2891131325 creator A5069656105 @default.
• W2891131325 creator A5073170147 @default.
• W2891131325 creator A5075059321 @default.
• W2891131325 creator A5076410856 @default.
• W2891131325 creator A5087131100 @default.
• W2891131325 creator A5087884003 @default.
• W2891131325 creator A5091186128 @default.
• W2891131325 date "2018-10-01" @default.
• W2891131325 modified "2023-10-18" @default.
• W2891131325 title "Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial" @default.
• W2891131325 cites W1880063947 @default.
• W2891131325 cites W1902873874 @default.
• W2891131325 cites W1917937632 @default.
• W2891131325 cites W1928621270 @default.
• W2891131325 cites W2036595545 @default.
• W2891131325 cites W2047778994 @default.
• W2891131325 cites W2060239344 @default.
• W2891131325 cites W2100241851 @default.
• W2891131325 cites W2107371365 @default.
• W2891131325 cites W2123377696 @default.
• W2891131325 cites W2124297369 @default.
• W2891131325 cites W2125452425 @default.
• W2891131325 cites W2129133229 @default.
• W2891131325 cites W2143655828 @default.
• W2891131325 cites W2144717403 @default.
• W2891131325 cites W2159919969 @default.
• W2891131325 cites W2210160876 @default.
• W2891131325 cites W2220709822 @default.
• W2891131325 cites W2305876893 @default.
• W2891131325 cites W2594825462 @default.
• W2891131325 cites W2623754168 @default.
• W2891131325 cites W2768209852 @default.
• W2891131325 cites W2768558125 @default.
• W2891131325 doi "https://doi.org/10.1097/dcr.0000000000001207" @default.
• W2891131325 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6130918" @default.
• W2891131325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192323" @default.
• W2891131325 hasPublicationYear "2018" @default.
• W2891131325 type Work @default.
• W2891131325 sameAs 2891131325 @default.
• W2891131325 citedByCount "102" @default.
• W2891131325 countsByYear W28911313252019 @default.
• W2891131325 countsByYear W28911313252020 @default.
• W2891131325 countsByYear W28911313252021 @default.
• W2891131325 countsByYear W28911313252022 @default.
• W2891131325 countsByYear W28911313252023 @default.
• W2891131325 crossrefType "journal-article" @default.
• W2891131325 hasAuthorship W2891131325A5004074211 @default.
• W2891131325 hasAuthorship W2891131325A5010136395 @default.
• W2891131325 hasAuthorship W2891131325A5015050276 @default.
• W2891131325 hasAuthorship W2891131325A5016541773 @default.
• W2891131325 hasAuthorship W2891131325A5026922437 @default.
• W2891131325 hasAuthorship W2891131325A5027858056 @default.
• W2891131325 hasAuthorship W2891131325A5029701783 @default.
• W2891131325 hasAuthorship W2891131325A5044015707 @default.
• W2891131325 hasAuthorship W2891131325A5047787817 @default.
• W2891131325 hasAuthorship W2891131325A5060087499 @default.
• W2891131325 hasAuthorship W2891131325A5060248836 @default.
• W2891131325 hasAuthorship W2891131325A5063518326 @default.
• W2891131325 hasAuthorship W2891131325A5064525249 @default.
• W2891131325 hasAuthorship W2891131325A5069656105 @default.
• W2891131325 hasAuthorship W2891131325A5073170147 @default.
• W2891131325 hasAuthorship W2891131325A5075059321 @default.
• W2891131325 hasAuthorship W2891131325A5076410856 @default.
• W2891131325 hasAuthorship W2891131325A5087131100 @default.
• W2891131325 hasAuthorship W2891131325A5087884003 @default.
• W2891131325 hasAuthorship W2891131325A5091186128 @default.
• W2891131325 hasBestOaLocation W28911313252 @default.
• W2891131325 hasConcept C121608353 @default.
• W2891131325 hasConcept C126322002 @default.
• W2891131325 hasConcept C141071460 @default.
• W2891131325 hasConcept C2776694085 @default.
• W2891131325 hasConcept C2777201421 @default.
• W2891131325 hasConcept C2778260052 @default.
• W2891131325 hasConcept C2778424827 @default.
• W2891131325 hasConcept C2779804826 @default.
• W2891131325 hasConcept C2780456651 @default.
• W2891131325 hasConcept C2780962732 @default.
• W2891131325 hasConcept C31760486 @default.
• W2891131325 hasConcept C526805850 @default.
• W2891131325 hasConcept C71924100 @default.
• W2891131325 hasConcept C90924648 @default.
• W2891131325 hasConceptScore W2891131325C121608353 @default.
• W2891131325 hasConceptScore W2891131325C126322002 @default.

• next